StreetInsider.com News Articles

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

Tue, 23 Jun 2026 08:30:00 -0400

BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany.

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO International Convention this week, the Company has officially received formal

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

Tue, 23 Jun 2026 08:30:00 -0400

BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany.

BioMark secures US patent for urine-based lung cancer screening test

Tue, 09 Jun 2026 08:32:12 -0400

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) announced the United States Patent and Trademark Office issued a Notice of Patent Allowance for its urine-based lung cancer detection method.

The patent covers the use of urine to detect lung cancer, assess treatment response, screen at-risk populations, and evaluate drug efficacy using polyamine metabolites and other analytes. The allowed patent is titled "Method of Detecting Lung Cancer" and was filed under Application No. 18/304,741.

The Vancouver-based company's technology uses clinical mass spectrometry and metabolomic profiling to identify metabolic signatures associated with cancer. The patent covers five applications: detection and diagnosis of lung

BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

Tue, 09 Jun 2026 08:30:00 -0400

New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies.

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Patent Allowance for Application No. 18/304,741, titled "Method of Detecting Lung Cancer." The allowed patent covers the proprietary use of urine to detect lung cancer, assess treatment response,

BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

Tue, 09 Jun 2026 08:30:00 -0400

New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies.

BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

Tue, 14 Apr 2026 08:30:00 -0400

BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum. The presentation will take place in front of a panel of experts on Wednesday, April 15, 2026, at the Calgary TELUS Convention

BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

Tue, 14 Apr 2026 08:30:00 -0400

BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Thu, 15 Jan 2026 08:30:00 -0400

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities

Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Thu, 15 Jan 2026 08:30:00 -0400

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities

BioMark: 2025 Achievements & 2026 Vision

Wed, 31 Dec 2025 08:30:00 -0400

Celebrating A Year of Extraordinary Achievement

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux.

Dear BioMark Shareholders and Team,

As we reflect on 2025, we celebrate a transformative year that positions BioMark as the leader in early cancer detection and precision diagnostics. What we've accomplished together represents not just scientific breakthroughs—it represents the resilience, dedication, and unwavering commitment of our team

BioMark: 2025 Achievements & 2026 Vision

Wed, 31 Dec 2025 08:30:00 -0400

Celebrating A Year of Extraordinary Achievement

Dear BioMark Shareholders and Team,

BioMark Diagnostics appoints James Lavender to board of directors

Tue, 30 Dec 2025 08:32:11 -0400

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) announced the appointment of James Lavender to its board of directors, effective following resolutions accepted at the company's annual general meeting held December 22, 2025.

Lavender and his investment group participated as major investors in BioMark's financing completed in March 2025. The Vancouver-based company develops liquid biopsy technologies for early cancer detection.

Lavender brings software development and enterprise sales experience from technology companies, with experience in scaling data-driven platforms. He has worked on expanding BioMark's use of artificial intelligence and machine learning to enhance clinical performance and scalability of metabolomics-based oncology diagnostics.

"We are

BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

Tue, 30 Dec 2025 08:30:00 -0400

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist

Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company's Annual General Meeting (AGM) held on December 22nd, 2025.

Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy

BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

Tue, 30 Dec 2025 08:30:00 -0400

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist

Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

Tue, 23 Dec 2025 08:30:00 -0400

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that it has officially initiated its ISO 15189 accreditation program with the Standards Council of Canada (SCC) for its medical laboratory in Quebec City. The accreditation process officially commenced on December 19, 2025.

BioMark has engaged the Standards Council of Canada (SCC) as its accrediting agency to ensure its laboratory operations meet the highest international

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

Tue, 23 Dec 2025 08:30:00 -0400

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026

BioMark has engaged the Standards Council of Canada (SCC) as its accrediting agency to ensure its laboratory operations meet the highest international

BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

Mon, 01 Dec 2025 08:30:00 -0400

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ Innovation Awards Gala. The award ceremony, held on November 27, 2025, celebrated the collaboration

BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

Mon, 01 Dec 2025 08:30:00 -0400

Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

Wed, 12 Nov 2025 08:30:00 -0400

Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30% over the next decade.

The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with BioMark's

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

Wed, 12 Nov 2025 08:30:00 -0400

Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis

The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with BioMark's

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

Tue, 07 Oct 2025 08:30:00 -0400

Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the company has been invited to participate in the landmark HANSE lung cancer screening trial in Germany. This strategic clinical collaboration with Prof. Dr. Jens Vogel-Claussen at Medizinische Hochschule Hannover, Prof. Dr. Martin Reck at LungenClinic Grosshansdorf, and Dr. Sabine Bohnet at Universitätsklinikum Schleswig-Holstein,

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

Tue, 07 Oct 2025 08:30:00 -0400

Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

Mon, 29 Sep 2025 08:30:00 -0400

Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer.

The newly granted Chinese patent (N° ZL 201980092723.X) and Japanese patent (N° 2023-111262) cover BioMark's technology for detecting lung cancer

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

Mon, 29 Sep 2025 08:30:00 -0400

Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.

The newly granted Chinese patent (N° ZL 201980092723.X) and Japanese patent (N° 2023-111262) cover BioMark's technology for detecting lung cancer

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

Tue, 12 Aug 2025 08:30:00 -0400

Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING") to explore the clinical application of BioMark's innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader North African region.

Partnership Addresses Critical Healthcare Need
Lung cancer represents a leading cause of cancer-related mortality in Tunisia, creating an urgent